Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High C...
In response to the growing threat of the H5N1 bird flu virus, the U.S. government has awarded a $176 million contract to Moderna Inc. (NASDAQ:MRNA)...
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Walgreens Boots Alliance, Inc. (NASDAQ:WBA) sh...
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recomm...
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend wh...
On Tuesday, Eli Lilly and Co (NYSE:LLY) announced a collaboration with Microsoft Corp (NASDAQ:MSFT)-backed OpenAI that will allow Lilly to lev...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 44.13% on an annualized basis producing an average annual return of 57.4...
Novavax (NASDAQ: NVAX) submitted an application to the FDA, seeking to amend its Emergency Use Authorization (EUA) and update its protein-based COV...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...